The CAVALLI study (NCT02055820) investigated the BCL2 inhibitor venetoclax in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line treatment for DLBCL [137]. Here, BCL2 is linked to diffuse large B-cell lymphoma.